X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (331) 331
immunotherapy (282) 282
oncology (270) 270
immune-related adverse events (234) 234
nivolumab (233) 233
ipilimumab (190) 190
humans (170) 170
melanoma (163) 163
cancer (143) 143
pembrolizumab (136) 136
immunology (106) 106
care and treatment (101) 101
metastatic melanoma (97) 97
immune-related adverse event (96) 96
adverse events (95) 95
immune checkpoint inhibitors (94) 94
metastasis (83) 83
patients (82) 82
male (80) 80
female (72) 72
lung cancer (70) 70
advanced melanoma (68) 68
aged (68) 68
chemotherapy (68) 68
middle aged (68) 68
open-label (68) 68
therapy (67) 67
case report (66) 66
complications and side effects (65) 65
toxicity (63) 63
antibodies, monoclonal - adverse effects (62) 62
immune checkpoint inhibitor (61) 61
analysis (59) 59
docetaxel (59) 59
cell lung-cancer (58) 58
checkpoint inhibitors (57) 57
management (53) 53
pd-1 (52) 52
cancer therapies (51) 51
antibodies, monoclonal - therapeutic use (49) 49
blockade (49) 49
immune-related response (49) 49
neoplasms. tumors. oncology. including cancer and carcinogens (49) 49
safety (49) 49
research (47) 47
animals (46) 46
anti-pd-1 (46) 46
pharmacology & pharmacy (43) 43
antineoplastic agents - adverse effects (42) 42
immune checkpoint (42) 42
programmed cell death 1 receptor - antagonists & inhibitors (42) 42
apoptosis (41) 41
lymphocytes (41) 41
survival (40) 40
immunotherapy - methods (39) 39
lung neoplasms - drug therapy (39) 39
melanoma - drug therapy (39) 39
drug therapy (38) 38
immune related adverse events (38) 38
immunotherapy - adverse effects (38) 38
tumors (38) 38
antibodies (37) 37
usage (35) 35
adult (34) 34
treatment outcome (34) 34
autoimmunity (33) 33
ctla-4 (33) 33
lung cancer, non-small cell (33) 33
medicine & public health (33) 33
review (33) 33
aged, 80 and over (32) 32
antigens (32) 32
clinical trials (32) 32
non-small cell lung cancer (32) 32
antineoplastic agents - therapeutic use (31) 31
respiratory system (31) 31
toxicities (31) 31
cell death (30) 30
antibody (29) 29
antineoplastic agents, immunological - adverse effects (29) 29
development and progression (29) 29
immune response (29) 29
immune system (29) 29
colitis (28) 28
immune‐related adverse events (28) 28
expression (27) 27
solid tumors (27) 27
checkpoint inhibitor (26) 26
monoclonal antibodies (26) 26
neoplasms - drug therapy (26) 26
patient (26) 26
pneumonitis (26) 26
biomarkers (25) 25
carcinoma, non-small-cell lung - drug therapy (25) 25
hepatitis (25) 25
immunoglobulins (25) 25
inflammatory bowel disease (25) 25
risk factors (25) 25
t cells (25) 25
anti-ctla-4 (24) 24
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gynecologic Oncology Reports, ISSN 2352-5789, 11/2019, Volume 30, p. 100508
Background: Immune checkpoint inhibitors (ICI) eliminate cancer cells through release of inhibition of cytotoxic CD8+ lymphocytes. Potent systemic activation... 
Immune toxicity | Immune-related adverse events | Immunotherapy | Melanoma
Journal Article
Cancer Letters, ISSN 0304-3835, 2015, Volume 371, Issue 1, pp. 48 - 61
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2018, Volume 36, Issue 4, pp. 638 - 646
Background Immunotherapy is emerging as the cornerstone for treatment of patients with advanced cancer, but significant toxicity (immune-related adverse events... 
Response | Checkpoint inhibitors | Medicine & Public Health | Immunotherapy | Systemic steroids | Time to progression | Oncology | Pharmacology/Toxicology | Immune-related adverse event | LYMPHOCYTE | ANTIBODY | METASTATIC MELANOMA | PEMBROLIZUMAB | TOXICITIES | ONCOLOGY | LONG-TERM SAFETY | PHARMACOLOGY & PHARMACY | NIVOLUMAB | CLINICAL-RESPONSE | IPILIMUMAB | Humans | Middle Aged | Risk Factors | Immunologic Factors - immunology | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Immunotherapy - adverse effects | Incidence | Young Adult | Neoplasms - therapy | Neoplasms - immunology | Aged, 80 and over | Adult | Female | Aged | Retrospective Studies | Antibodies, Monoclonal - immunology | Adrenal Cortex Hormones - administration & dosage | Treatment outcome | Care and treatment | Usage | Analysis | Medical records | Development and progression | Diagnosis | Research | Cancer | Immune system | Corticoids | Corticosteroids | Toxicity | Medical services | Lymphocytes T | Immune status | Enterocolitis | Risk analysis | Dermatitis | Patients | Electronic medical records | Clinical outcomes | Risk factors | Studies | Medical electronics | Electronic health records | Index Medicus | systemic steroids | time to progression | response | checkpoint inhibitors | immunotherapy | immune-related adverse event
Journal Article
ESMO Open, ISSN 2059-7029, 07/2019, Volume 4, Issue Suppl 4, p. e000540
Neurological adverse events from immune checkpoint inhibition are increasingly recognised, especially with combination anti-cytotoxic T-lymphocyte antigen 4... 
ONCOLOGY | NIVOLUMAB | ADVANCED MELANOMA
Journal Article
GE - Portuguese Journal of Gastroenterology, ISSN 2341-4545, 07/2019, Volume 26, Issue 4, pp. 268 - 274
Immune checkpoint inhibitors have shown anti-tumour activity in cancers such as melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial... 
Review Article | Diarrhoea | Colitis | Immune checkpoint inhibitor | Immune-related adverse event | Antigens | Immunoglobulins | Cytokines | Working groups | Melanoma | Diarrhea | FDA approval | Cancer therapies | Skin cancer | Inflammatory bowel disease | Algorithms | Lymphocytes | Immunotherapy | Ulcers | Drug dosages | Diarreia | Colite | Inibidores dos “checkpoint” imunológicos | Review
Journal Article
Seminars in Oncology Nursing, ISSN 0749-2081, 10/2019, Volume 35, Issue 5, p. 150934
To discuss future direction and present an overview of the evolution of immunotherapy long-term toxicity issues, financial toxicity, and new emerging... 
Financial toxicity | CAR T-cell therapy | Fertility | Immune related adverse events | Immune checkpoint inhibitors | Survivorship | T-VEC
Journal Article
Autoimmunity Reviews, ISSN 1568-9972, 10/2018, Volume 17, Issue 10, pp. 1040 - 1045
To evaluate the prevalence and type of rheumatic immune-related adverse events (IRAEs) in patients receiving programmed cell death protein-1 (PD-1) inhibitors.... 
Programmed cell death protein-1 inhibitors | Immune checkpoint inhibitors | Immunotherapy | Rheumatic immune-related adverse events | TOXICITY | IMMUNOLOGY | ARTHRITIS | CANCER | METASTATIC MELANOMA | CHECKPOINT INHIBITORS | PEMBROLIZUMAB | THERAPY | NIVOLUMAB | IPILIMUMAB | Complications and side effects | Myositis | Development and progression | Arthritis | Cell death
Journal Article
Current oncology (Toronto, Ont.), ISSN 1198-0052, 10/2018, Volume 25, Issue 5, pp. 342 - 347
Journal Article
Aquatic Toxicology, ISSN 0166-445X, 09/2019, Volume 214, p. 105254
Intracellular copper/zinc superoxide dismutase (icCuZnSOD) is a member of superoxide dismutase family that is capable of catalyzing the superoxide radicals... 
Nibea albiflora | Prokaryotic expression | Enzyme activity | icCuZnSOD | Ammonia/nitrite toxicity | OXIDATIVE STRESS | AMMONIA | PIARACTUS-MESOPOTAMICUS | IMMUNE-RELATED GENES | IDENTIFICATION | MARINE & FRESHWATER BIOLOGY | MULTIGENE FAMILY | MOLECULAR-CLONING | MN-SOD | TOXICOLOGY | NITRITE | EXPOSURE
Journal Article
Lung Cancer, ISSN 0169-5002, 2017, Volume 109, pp. 74 - 77
Journal Article
Revue des Maladies Respiratoires, ISSN 0761-8425, 11/2018, Volume 35, Issue 9, pp. 963 - 967
Introduction: Immune checkpoint inhibitors are becoming a standard treatment for many different cancers. Their toxicities are variable and include... 
Immune-related adverse events | Toxicity | Immunotherapy | Granulomatosis | PD-1/PD-L1 inhibitors
Journal Article
Case Reports in Oncology, ISSN 1662-6575, 10/2019, Volume 12, Issue 3, pp. 820 - 828
Immune checkpoint inhibitors (ICIs), including anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) and anti-programmed death receptor-1/ligand-1... 
Case Report | toxicity | pembrolizumab | immune related adverse events | immunotherapy | melanoma | pancytopenia | anti-pd-1
Journal Article
JOURNAL FOR IMMUNOTHERAPY OF CANCER, ISSN 2051-1426, 07/2019, Volume 7
Background: The risk of delayed autoimmunity occurring months or years after discontinuation of immunotherapy is frequently asserted in the literature.... 
Checkpoint inhibitor | NEUROLOGICAL TOXICITIES | Immune-related adverse events | SOLID TUMORS | ADRENAL INSUFFICIENCY | Costimulatory agonist | OPEN-LABEL | IMMUNOLOGY | CHECKPOINT INHIBITORS | MELANOMA | ONCOLOGY | Immunotherapy | Delayed toxicity | CLINICAL ACTIVITY | PHASE-I | ADVERSE EVENTS | IPILIMUMAB
Journal Article
Ecotoxicology, ISSN 0963-9292, 07/2017, Volume 26, Issue 5, pp. 702 - 710
Journal Article